Scholars Central

Rapid communicationPublished 29 Dec 2025

PI3K Pathway: Targeting Ovarian Cancer Therapeutics

Authors: Dr. Nathan Wright

University of Toronto, Canada

Insights in Gynecologic Oncology

Volume 10 · Issue 6 · Pages 1–3

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The PI3K pathway is a critical signaling cascade frequently dysregulated in ovarian cancer, driving proliferation, survival, and resistance to therapy. Targeting this pathway offers a promising therapeutic strategy, with several PI3K inhibitors showing activity. Understanding PI3K isoforms and resistance mechanisms is key. The PI3K/AKT/mTOR pathway regulates tumorigenesis and progression. PIK3CA mutations are common, emphasizing isoform-specific targeting. Preclinical studies show efficacy for novel inhibitors, and research addresses resistance via combinations. Clinical trials are evaluating PI3K inhibitors in recurrent disease. The pathway’s role in the tumor microenvironment and chemoresistance is under investigation. Isoform-selective inhibitors aim for improved efficacy and safety.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalInsights in Gynecologic Oncology
  • SubjectOncology & Cancer
  • SubjectReproductive Medicine & Gynaecology
  • BylineArticles whose byline prints “Dr. Nathan Wright”